A recent study examined the outcomes of care for RA patients provided by nurse practitioners or physician assistants working in tandem with rheumatologists, compared with that provided exclusively by rheumatologists. Over the two-year course of the study, results indicated that not only was care not compromised, but RA disease activity control may actually have been slightly better in these practices…
Etanercept Biosimilars Promising in Clinical Studies
In multiple clinical studies, investigational biosimilars for etanercept were shown to be safe and effective for treating rheumatoid arthritis and moderate to severe plaque psoriasis…
Bronchial Tissue Immune Activation Seen in Early Rheumatoid Arthritis
NEW YORK (Reuters Health)—Patients with untreated early rheumatoid arthritis (RA) show signs of immune activation and local inflammation in their bronchial tissues, researchers from Sweden report. Previous studies have shown that patients with RA have shared citrullinated epitopes in the lungs and joints, as well as anticitrullinated protein antibodies (ACPA) in bronchoalveolar lavage (BAL), suggesting…
Does Methotrexate Increase Skin Cancer Risk?
A recent study connects the use of immunosuppressant and biologic agents to an increased risk of nonmelanoma skin cancer in patients being treated for RA and IBD…
Higher Tocilizumab Dose Plus Methotrexate Best for Early RA
NEW YORK (Reuters Health)—Tocilizumab improves remission rates and slows disease progression in patients with early rheumatoid arthritis (RA), a new randomized controlled trial demonstrates. Tocilizumab was effective both on its own and when combined with methotrexate, Dr. Gerd R. Burmester of Charite Medical University of Berlin and his colleagues found. Tocilizumab, an interleukin-6 (IL-6) blocker,…
CD64 May Be an RA-Specific Biomarker
A new study found patients with early RA had increased membrane and soluble CD64. After receiving anti-rheumatic therapy, patients’ symptoms and CD64 levels decreased, suggesting CD64 is an RA biomarker…
Rheumatoid Arthritis Patients Have More Severe ACS, Poorer Outcomes
NEW YORK (Reuters Health)—Rheumatoid arthritis (RA) is associated with more-severe acute coronary syndrome and poorer outcomes, according to a new study. “We found that despite the well-researched increased risk of acute coronary events (ACS) in RA, that there was almost no existing data describing clinical characteristics and outcomes of RA- and non-RA patients with ACS,”…
Rituximab for RA Is Safe Long Term, Plus Oxycodone Update
Rituximab was evaluated and found safe as a long-term RA therapy. Also, FDA Advisory Committees voted on oxycodone therapies at a joint meeting.
IL-26 Plays Antimicrobial Role in Immune Response
Researchers determined IL-26 serves as a potent antimicrobial that promotes the immune sensing of both bacterial and host cell death…
Methotrexate Halt Feasible in Some Etanercept RA Responders
NEW YORK (Reuters Health)—Certain rheumatoid arthritis (RA) patients doing well on etanercept and methotrexate may be able to quit the latter agent if they have tolerability problems, according to an open-label Canadian study. In a Sept. 11 online paper in Rheumatology, Dr. Boulos Haraoui, of the University of Montreal, and colleagues noted that although combination…
- « Previous Page
- 1
- …
- 24
- 25
- 26
- 27
- 28
- …
- 30
- Next Page »